Globally significant milestones: 1) world-leading accuracy of stress measurement from mobile selfies, 2) first organisation to show app-based meditation can outperform placebo, 3) objective personalisation delivering 2.5x efficacy - proving that precision psychiatry can be scaled. The company’s intervention treating cancer-related post traumatic stress is expected to receive regulatory clearance by the FDA, Health Canada and Singapore’s HSA in 2023.
Problem or Opportunity
Mental healthcare has two massive challenges: 1) Meeting the large and increasing demand for care, and 2) Identifying what treatment is best for each patient.
Solution (product or service)
Mobio Interactive has invented a revolutionary new approach that solves both mental healthcare challenges. By delivering clinically validated therapy on the phone asynchronously and on-demand, the company has solved the first challenge. Meanwhile, they solve the second challenge by quantifying the efficacy of therapy in real-time with computer vision and AI without a wearable. The result is precision psychiatry at scale for the first time in history.
Business model
We are adopting the regulatory-approved and payor-reimbursed pharmaceutical model to digital therapeutics, leading to full integration of our software as medicine into the healthcare economy.
To accelerate and de-risk this business objective, we are simultaneously commercialising our technology via routes that do not require regulatory approval (Class I SaMD). This “near-term” approach has the added benefit of generating immediate revenues, while establishing the networks and collaborations needed to command market leading status following regulatory approval of Class II SaMD interventions.
Incubation/Acceleration programs accomplishment
MedTech Innovator APAC, H+ Digital Health Innovation Programme, BioFM Incubator, Ontario Bioscience Innovation Organization Health to Business Bridge Programme, Canadian Technology Accelerator, BioMedical Zone, Vienna Start-up Package, Chinaccelerator
